Cresco Labs Inc. (CRLBF) Cash & Equivalents (2019 - 2026)

Cresco Labs (CRLBF) has reported Cash & Equivalents for 8 consecutive years, with $32.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 78.52% year-over-year to $32.9 million; the trailing twelve-month figure through Jun 2026 stood at $32.9 million (down 78.52% YoY), and the FY2025 full-year result was $57.9 million, down 57.91% from the prior year.
• Cash & Equivalents eased to $32.9 million in Q2 2026 per CRLBF's latest filing, from $66.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $226.1 million in Q1 2022 and bottomed at $32.9 million in Q2 2026.
• Historically, Cash & Equivalents has averaged $112.8 million across 5 years, with a median of $116.1 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents surged 59.34% in 2024, then plunged 78.52% in 2026.
• Over 5 years, Cash & Equivalents stood at $132.3 million in 2022, then dropped by 21.83% to $103.4 million in 2023, then surged by 33.0% to $137.6 million in 2024, then slumped by 57.91% to $57.9 million in 2025, then tumbled by 43.23% to $32.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $32.9 million, $66.8 million, and $57.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.